Pheast is a clinical-stage immuno-oncology company focused on activating the innate immune system in the fight against cancer. Founded on breakthrough research from Dr. Irv Weissman’s lab at Stanford University and led by scientific experts in innate immunity and cancer immunotherapy, Pheast is developing novel therapies for some of the most difficult-to-treat and aggressive cancers. Pheast is backed by leading life sciences investors, including Catalio Capital Management and ARCH Venture Partners. F
